Iranian Red Crescent Medical Journal

Published by: Kowsar

Liver Function and Anemia Pathogenesis in Iranian Traditional Medicine

Saeedeh Yarjou 1 , Omid Sadeghpour 2 , Esmail Nazem 3 and Amir Hossein Emami 4 , *
Authors Information
1 Department of Traditional Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Herbal Medicine, Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, IR Iran
3 Faculty of Traditional Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Hematology/Oncology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: December 01, 2014, 17 (1); e17099
  • Published Online: December 15, 2014
  • Article Type: Brief Report
  • Received: December 24, 2013
  • Revised: April 29, 2014
  • Accepted: June 16, 2014
  • DOI: 10.5812/ircmj.17099

To Cite: Yarjou S, Sadeghpour O, Nazem E, Emami A H. Liver Function and Anemia Pathogenesis in Iranian Traditional Medicine, Iran Red Crescent Med J. 2014 ; 17(1):e17099. doi: 10.5812/ircmj.17099.

Abstract
Copyright © 2014, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Moore E, Bellomo R. Erythropoietin (EPO) in acute kidney injury. Annals of Intensive Care. 2011; 1(1): 3[DOI]
  • 2. Moreno Chulilla JA, Romero Colas MS, Gutierrez Martin M. Classification of anemia for gastroenterologists. World J Gastroenterol. 2009; 15(37): 4627-37[PubMed]
  • 3. Wiener C, Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, et al. Harrisons Principles of Internal Medicine. 2012;
  • 4. Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007; 13(12): 1545-53[DOI][PubMed]
  • 5. Jorjani SE. Zakhireh Kharazmshahi. 2012;
  • 6. Azam M. Research Institute for Islamic and Complementary Medicine. 1387;
  • 7. Avicenna H. Al-Qanun fi'l-Tibb (Canon of Medicine). 1993;
  • 8. Garshi AA,. Explanation of Canon, Handwritten Manuscript.
  • 9. Jensen JD, Jensen LW, Madsen JK, Poulsen L. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol. 1995; 54(2): 111-6[PubMed]
  • 10. Bruno CM, Neri S, Sciacca C, Bertino G, Di Prima P, Cilio D, et al. Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases. World J Gastroenterol. 2004; 10(9): 1353-6[PubMed]
  • 11. Tacke F, Luedde T, Manns MP, Trautwein C. Regulation of plasma erythropoietin in chronic liver disease. World J Gastroenterol. 2004; 10(19): 2922-3[PubMed]
  • 12. Madro A, Kurzepa J, Czechowska G, Slomka M, Celinski K, Szymonik-Lesiuk S. Erythropoietin inhibits liver gelatinases during galactosamine-induced hepatic damage in rats. Pharmacol Rep. 2009; 61(5): 917-23[PubMed]
  • 13. Greif F, Ben-Ari Z, Taya R, Pappo O, Kurtzwald E, Cheporko Y, et al. Dual effect of erythropoietin on liver protection and regeneration after subtotal hepatectomy in rats. Liver Transpl. 2010; 16(5): 631-8[DOI][PubMed]
  • 14. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest. 2003; 33(10): 891-6[PubMed]
  • 15. Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int. 2006; 19(11): 919-26[DOI][PubMed]
  • 16. Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. "Silymarin", a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 2011; 14(4): 308-17[PubMed]
  • 17. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102(3): 783-8[DOI][PubMed]
  • 18. Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica. 2010; 95(2): 175-8[DOI][PubMed]
  • 19. Parsian H. Is the aspartate transaminase to platelet ratio index adequate for the assessment of liver fibrosis in patients with chronic liver disease? Hepat Mon. 2011; 11(5): 380-1[PubMed]
  • 20. Leonardi S, Vitaliti G. Liver fibrosis in patients with chronic liver diseases: are laboratory tests useful to diagnosis? Hepat Mon. 2011; 11(5): 382-3[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments